Scarica l'app Stockscreener
343.60
8.39%
26.60
Pre-mercato:
343.60
Praxis Precision Medicines Inc Borsa (PRAX) Ultime notizie
Praxis Precision gains as lead asset accepted for FDA review - MSN
PRAX Reiterated by Needham -- Price Target Maintained at $510 - GuruFocus
FDA accepts Praxis Precision Medicines’ NDA for ulixacaltamide in essential tremor - Investing.com Australia
Praxis Precision NDA for Ulixacaltamide in Essential Tremor - TipRanks
FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor - Stock Titan
Jones Trading reiterates Praxis Precision Medicines stock Buy rating on FDA filing acceptance - Investing.com UK
Why Is Praxis Precision Stock Soaring Tuesday? - Benzinga
Jefferies reiterates Praxis Precision Medicines stock rating on FDA review - Investing.com
Praxis Precision Medicines stock rating reiterated at Buy by BTIG - Investing.com
Jefferies reiterates Praxis Precision Medicines stock rating on FDA review By Investing.com - Investing.com Australia
Needham Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $510 - Moomoo
Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application - marketscreener.com
Praxis Precision gets FDA review for lead asset (PRAX:NASDAQ) - Seeking Alpha
Praxis Precision Medicines Announces FDA Acceptance of NDA for Ulixacaltamide HCl for Essential Tremor Treatment, Target Action Date Set for January 29, 2027 - Quiver Quantitative
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor - Bitget
FDA starts Praxis review for essential tremor drug, decision due Jan. 2027 - Stock Titan
(PRAX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Praxis to Showcase Essential3, the First Positive Phase 3 Program in Essential Tremor, at AAN 2026 - National Today
7 million Americans with essential tremor see a first positive Phase 3 program - Stock Titan
Raymond James Initiates Praxis Precision Medicines at Strong Buy With $815 Price Target - marketscreener.com
Raymond James initiates Praxis Precision Medicines stock coverage with Strong Buy - Investing.com
A Look At Praxis Precision Medicines (PRAX) Valuation After Positive Elsunersen Seizure Reduction Data - simplywall.st
Praxis Precision Medicines (PRAX) reports $926M 2025 cash balance, extended runway - MSN
PRAX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Wolfe Research Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating, Maintains Target Price $500 - Moomoo
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $500 to $1,245 - Moomoo
Praxis Adds To Neuroscience Momentum With Epilepsy Trial Success - Citeline News & Insights
H.C. Wainwright reiterates Praxis Precision stock rating on trial data By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Praxis Precision stock rating on trial data - Investing.com
HC Wainwright Reiterates Buy Rating for Praxis Precision Medicines (NASDAQ:PRAX) - MarketBeat
HC Wainwright & Co. Reiterates Buy Rating for PRAX with $1245 Ta - GuruFocus
Praxis Precision Medicines Announces Positive EMBRAVE Part A Trial Results for Elsunersen in Pediatric SCN2A Epileptic Encephalopathy - Minichart
Praxis Precision Medicines reports positive trial results for elsunersen and FDA review of relutrigine - Investing.com Australia
Praxis reports positive elsunersen trial in pediatric epilepsies - TipRanks
Praxis Precision Medicines reports positive trial results for elsunersen and FDA review of relutrigine By Investing.com - Investing.com South Africa
Praxis Precision reports positive Phase 1/2 elsunersen results; FDA sets PDUFA for relutrigine - TradingView — Track All Markets
Praxis (PRAX) reports positive elsunersen seizure data and FDA priority review for relutrigine - Stock Titan
Praxis: Strong Buy As Relutrigine Submission Accepted Plus Expansion Potential (PRAX) - Seeking Alpha
PRAX: BTIG Reiterates Buy Rating and Maintains Price Target | PR - GuruFocus
Praxis rises on elsunersen data for SCN2A encephalopathy in children - MSN
PRAX: BTIG Reiterates Buy Rating and Maintains Price Target | PRAX Stock News - gurufocus.com
BTIG Research Reaffirms "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX) - marketbeat.com
Praxis Stock Rises After Elsunersen Shows 77% Seizure Reduction In TrialPraxis Precision Medicine (NAS - Benzinga
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy - Investing News Network
Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic Encephalopathy - TradingView — Track All Markets
In a nine-patient Praxis trial, children had 77% fewer seizures - Stock Titan
A Look At Praxis Precision Medicines (PRAX) Valuation After FDA Priority Review For Relutrigine - Yahoo Finance
Aberdeen Group plc Takes $39.79 Million Position in Praxis Precision Medicines, Inc. $PRAX - MarketBeat
PRAX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
SG Americas Securities LLC Cuts Position in Praxis Precision Medicines, Inc. $PRAX - marketbeat.com
(PRAX) Risk Channels and Responsive Allocation - Stock Traders Daily
0.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):